The recognition of SCLC transformation as a recurrent resistance phenotype has prompted investigation into its biological basis, particularly whether EGFR-mutant adenocarcinoma and SCLC derive from a shared progenitor population capable of lineage plasticity under therapeutic pressure. Here, EGFR is linked to adenocarcinoma.